For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
MAC27 - COMPASSHER2 residual disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and Tucatinib has closed to accrual.
CCTG was pleased to present the Excellence in Clinical Trials Conduct award to Iryna Sokolenko at North York General Hospital for her work to support our trials and contributions to patient-focused research. Iryna is the PCRA for CRC.10 and has been recognized as having exceptional attention to detail who's genuine care made participating in the trial a positive experience for patients. This is presented annually to an individual who exemplifies excellence in clinical trial operations and compliance at their institution.
We are honoured to announce that the 2025 Joseph Pater Founder’s Award for Excellence in Clinical Trials Research has been presented to Dr. Rebecca Wong Princess Margaret Cancer Centre for her many years of trial and committee leadership with the group.She was Chair of CCTG’s Symptom Control (now Supportive Care) Committee from 2001-2018, and Esophageal disease-oriented group from 2009-2018. She is currently a member of CCTG’s Clinical Trials Committee.
The Investigational New Drug Program Team Award was presented to the IND.244 team at CHU de Québec – Hôpital L’Enfant-Jésus for their work activating and recruiting patients to this trial. Awarded at the CCTG Spring Meeting to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in a CCTG IND clinical trial to acknowledge their efforts and dedication to the success of clinical trials.
The Ralph Meyer Phase III Program Young Investigator Award has been awarded to Dr. Rachel Glicksman from Princess Margaret Cancer Centre recognizing her active participation and enrollment activities as a young investigation in CCTG trials. This award is presented to individuals who have made significant contributions to the phase III program research projects.
It was an honour to recognize Judy Needham with the Excellence in Clinical Trials Conduct – Patient Engagement award for her unwavering commitment to patient engagement at CCTG. Judy joined CCTG as a Patient Representative in May 2012 on the Breast Site Committee and became the Chair, CCTG Patient Representatives Committee, in 2014, she successfully led the PRC for over 10 years stepping down this year.
Congratulations to Dr. Moira Rushton, a Medical Oncologist from the Ottawa Hospital Research Institute who has been awarded the Elizabeth Eisenhauer Early Drug Development Young Investigator Award for her work on CCTG IND trials and committees.
“I am truly honored to have been selected as the recipient of this year’s Elizabeth Eisenhauer early drug development young investigator award. My time at CCTG was an invaluable formative experience and continues to meaningfully impact my clinical practice and academic career,” says Dr Rushton.
